adult nodular lymphocyte predominant Hodgkin lymphoma

Summary

adult nodular lymphocyte predominant Hodgkin lymphoma (MONDO:0019478) is a cancer and 8 clinical trials. Top therapeutic interventions include rituximab, bendamustine hydrochloride, and panobinostat. A subtype of adult lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult nodular lymphocyte predominant Hodgkin lymphoma
Mondo ID	MONDO:0019478
NCIT	C7942
UMLS	C1332210
MedGen	231044
GARD	0025137
Is cancer (heuristic)	yes

Also known as: adult NLPHD · adult nodular lymphocyte predominant Hodgkin’s disease · adult nodular lymphocyte predominant Hodgkin’s lymphoma · nodular lymphocyte predominant Hodgkin lymphoma

Data availability: 1 cell line.

Disease family

This is a subtype of adult lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › adult lymphoma › adult nodular lymphocyte predominant Hodgkin lymphoma

Related subtypes (1): adult T-cell leukemia/lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1/PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003820	PHASE2	COMPLETED	Rituximab in Treating Patients With Hodgkin’s Lymphoma
NCT00132028	PHASE2	COMPLETED	Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin’s Lymphoma
NCT00288067	PHASE1/PHASE2	TERMINATED	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00381940	PHASE2	COMPLETED	Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
NCT01460940	PHASE2	COMPLETED	A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin’s Lymphoma
NCT01535924	PHASE1/PHASE2	COMPLETED	Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin’s Lymphoma
NCT01588015	PHASE1	COMPLETED	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
NCT04858568	Not specified	COMPLETED	Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	2
BENDAMUSTINE HYDROCHLORIDE	4	1
PANOBINOSTAT	4	1
VINORELBINE TARTRATE	4	1
VORINOSTAT	4	1
FENRETINIDE	3	1
CHEMBL344227	0	1